These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 24182673)

  • 1. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study.
    Bosselmann H; Egstrup M; Rossing K; Gustafsson I; Gustafsson F; Tonder N; Kistorp CN; Goetze JP; Schou M
    Int J Cardiol; 2013 Dec; 170(2):202-7. PubMed ID: 24182673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
    Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
    Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.
    Ahluwalia N; Blacher J; Szabo de Edelenyi F; Faure P; Julia C; Hercberg S; Galan P
    Atherosclerosis; 2013 Jun; 228(2):478-84. PubMed ID: 23582589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
    J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of renal impairment on myocardial function in outpatients with systolic heart failure: an echocardiographic and cardiac biomarker study.
    Bosselmann H; Tonder N; Sölétormos G; Rossing K; Iversen K; Goetze JP; Gustafsson F; Schou M
    Int J Cardiol; 2014 Dec; 177(3):942-8. PubMed ID: 25449505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of proBNP1-108 testing for the risk stratification of patients with systolic heart failure.
    Gruson D; Lepoutre T; Ahn SA; Rousseau MF
    Peptides; 2013 Dec; 50():125-8. PubMed ID: 24140405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure.
    Schou M; Gustafsson F; Kistorp CN; Corell P; Kjaer A; Hildebrandt PR
    Am J Cardiol; 2007 Nov; 100(10):1571-6. PubMed ID: 17996522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in N-terminal pro-brain natriuretic peptide levels, renal function and cardiac disease in the oldest old.
    Poortvliet R; de Craen A; Gussekloo J; de Ruijter W
    Age Ageing; 2015 Sep; 44(5):841-7. PubMed ID: 26209786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure.
    Perna ER; Macin SM; Cimbaro Canella JP; Szyszko A; Franciosi V; Vargas Morales W; Bayol AP; Kriskovich JO; Medina F; Gonzalez Arjol B; Brizuela M
    J Heart Lung Transplant; 2006 Oct; 25(10):1230-40. PubMed ID: 17045936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
    O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA
    J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients.
    Schou M; Bosselmann H; Gaborit F; Iversen K; Goetze JP; Soletomas G; Rasmussen J; Kistorp C; Kober L; Gustafsson F; Tonder N
    Int J Cardiol; 2015 Sep; 195():143-8. PubMed ID: 26043148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease.
    Chrysochou C; Manzoor S; Wright J; Roberts SA; Wood G; McDowell G; Kalra PA
    Kidney Blood Press Res; 2009; 32(5):373-9. PubMed ID: 19887825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
    Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
    Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure.
    Tsutamoto T; Kawahara C; Nishiyama K; Yamaji M; Fujii M; Yamamoto T; Horie M
    Am Heart J; 2010 Jan; 159(1):63-7. PubMed ID: 20102868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.
    Pascual-Figal DA; Manzano-Fernández S; Boronat M; Casas T; Garrido IP; Bonaque JC; Pastor-Perez F; Valdés M; Januzzi JL
    Eur J Heart Fail; 2011 Jul; 13(7):718-25. PubMed ID: 21551163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.